However, there is still a lack of inhibitors or agonists of the TGF-β/SMADs signaling pathway in large-scale clinical trials, coupled with the two-sidedness of this pathway in the process of cardiac obstruction, further research is needed on the effects of targeted drugs and timing of drug use on patients with MI. This evidence concerns the gene TGFB1 and myocardial infarction.